Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer

Autor: Han Fu, Xue Han, Wenqing Guo, Xuening Zhao, Chunxue Yu, Wei Zhao, Shasha Feng, Jian Wang, Zhenshuai Zhang, Kaijian Lei, Ming Li, Tianxiao Wang

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)

Abstract Tamoxifen (TAM) resistance is a major challenge in treating oestrogen receptor-positive (ER+) breast cancers. It is possible that the H2S synthase cystathionine-γ-lyase (CSE), which has been previously shown to promote tumour growth and met

Externí odkaz: https://doaj.org/article/fe8ba047515f4f4790a552ca075c91b0

Using a fixed-jaw technique to achieve superior delivery accuracy and plan quality in single-isocenter multiple-target stereotactic radiosurgery for brain metastases

Autor: Jialu Lai, Shoupeng Liu, Jia Liu, Yuming Jia, Kaijian Lei, An Li, Zhonghua Deng, Bin Li, Haitao Wang, Lin Zhou

Publikováno v: Journal of Radiation Research and Applied Sciences, Vol 15, Iss 2, Pp 76-83 (2022)

To quantify the influence of the minimum dynamic leaf gap (DLG) on delivery accuracy and plan quality and determine whether the fixed-jaw technique can be used to reduce the adverse effects of DLG in single-isocenter volumetric modulated arc therapy

Externí odkaz: https://doaj.org/article/de397f4a33de41309feddbc7e58db81d

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Autor: Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu

Publikováno v: Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)

Abstract Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized con

Externí odkaz: https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922e